Insilico's AI-discovered drug rentosertib enters phase 3 in idiopathic pulmonary fibrosis
Insilico's AI-discovered rentosertib has entered a phase 3 trial in idiopathic pulmonary fibrosis, according to a report of 14 September 2026.
Who is affected and how
- pharmaceuticals
- One of the most closely studied AI-discovered molecules has reached the pivotal stage, which may serve as a benchmark for evaluating AI-derived pipelines.
Sources
- Insilico's AI-Discovered Drug Rentosertib Enters Phase 3 IPF Trial Studychemdiv.com · Sep 14, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.